News | Deal AnnouncementSVB Securities Serves as Joint Bookrunner for Natera’s (Nasdaq: NTRA) $400 Million Follow-On OfferingNovember 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Lantheus (NASDAQ: LNTH) on its Exclusive Licensing Agreements with Point Biopharma (NASDAQ: PNT)November 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Molded Devices, Inc. (MDI), a Portfolio Company of TruArc Partners, on its Acquisition of GlobalMedNovember 2022
News | Deal AnnouncementSVB Securities Serves as Lead-Left Bookrunner for Marinus Pharmaceuticals’ (Nasdaq: MRNS) $60 Million Follow-On OfferingNovember 2022
News | Deal AnnouncementSVB Securities Serves as Financial Advisor to Lumanity on its Acquisition of Clarion HealthcareNovember 2022
News | NewsSVB Securities Continues Growth of Technology Investment Banking Team with Addition of Roger KnightOctober 2022
News | NewsSVB Securities Expands Technology Equity Trading with the Addition of Amy ChampionAugust 2022
News | NewsSVB Securities Continues Expansion of its Technology Equity Research Team with the Addition of Jackson AderJuly 2022
News | NewsSVB Securities Expands Institutional Equities Team with the Additions of Dana Herrman and Rishi DesaiJune 2022
News | NewsSVB Securities Expands Technology Equity Research Team with the Addition of Michael Morton, CFAApril 2022
News | NewsSVB Securities Strengthens Tech Investment Banking Team with the Addition of Georgi BalinovMarch 2022
